FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to radio@fiercebiotech.com.

This week's episode is sponsored by Catalent.

Read more on